您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Ramiprilat
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ramiprilat
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Ramiprilat图片
CAS NO:87269-97-4
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍

化学性质

Physical AppearanceA crystalline solid
StorageStore at -20°C
M.Wt388.5
Cas No.87269-97-4
FormulaC21H28N2O5
SynonymsRamipril Diacid
Solubility≤1mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide
Chemical Name(2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]octahydro-cyclopenta[b]pyrrole-2-carboxylic acid
Canonical SMILESO=C([C@H](C)N[C@H](C(O)=O)CCC1=CC=CC=C1)N2[C@]3([H])[C@](CCC3)([H])C[C@H]2C(O)=O
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

pKi= 9.08 in human heart

Ramiprilat is an angiotensin-converting enzyme (ACE) inhibitor.

ACE inhibitors help relax blood vessels and prevent an enzyme from producing angiotensin II, a substance narrowing blood vessels and releasing hormones that can raise blood pressure.

In vitro: Pretreatment with ramiprilat could significantly attenuate the recovery of B2 kinin receptors in while increasing that from membranes lacking caveolin, and such effect was not because of the inhibition of bradykinin degradation. Ramiprilat could also decrease [3H]bradykinin binding to CR membranes. In addition, ramiprilat treatment led to reactivation of the B2 receptor in bradykinin-stimulated cells [1].

In vivo: In previous animal study, when compared with the control rats, diabetic rats showed decreased creatinine clearance rate, increased urinary protein excretion and blood pressure, as well as development of tubulointerstitial fibrosis, glomerulosclerosis, and inflammatory cell infiltration. Furthermore, the blocking angiotensin II with ramipril (the prodrug of ramiprilat) was able to significantly improve all of these parameters [2].

Clinical trial: Previous study showed that ramipril at 10 mg/day could significantly reduce the incidence of MI, stroke or death from cardiovascular causes in patients who were at increased risk for the development of ischaemic cardiovascular events [3].

References:
[1] T.  Benzing, I. Fleming, A. Blaukat, et al. Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 99(15), 2034-2040 (1999).
[2] Li C, Yang CW, Park CW, Ahn HJ, Kim WY, Yoon KH, Suh SH, Lim SW, Cha JH, Kim YS, Kim J, Chang YS, Bang BK.  Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats. Kidney Int. 2003 Feb;63(2):454-63.
[3] Warner GT, Perry CM.  Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs. 2002;62(9):1381-405.